CleanSpace Appoints Robert G. as Chief Strategy Officer

CleanSpace Appoints Robert G. as Chief Strategy Officer to Lead Turnkey Expansion and Launch of CleanShield Division

Doylestown, PA – [April 2025] — CleanSpace, the nation’s leading fully integrated modular cleanroom design-build firm, proudly announces the appointment of Robert G. as Chief Strategy Officer. With over 30 years of experience in sterile injectable pharmaceutical manufacturing and facilities management, Griffith brings unmatched expertise from the owner’s side of the industry—having led large capital programs and regulatory transformations at top-tier organizations including Endo, PAR Pharmaceutical, and JHP Pharmaceuticals.

As CSO, Griffith will oversee the expansion and national rollout of CleanShield, CleanSpace’s dedicated service division for after-construction support. CleanShield will deliver a comprehensive suite of services including ongoing facility maintenance, emergency response, small projects, and a client-integrated workforce development program. CleanShield will also be responsible for the execution of technical documentation, client training programs, and full Commissioning, Qualification, and Validation (CQV) support—the most critical and challenging stage of any life science facility launch.

“With the addition of Robert and the integration of CleanShield, CleanSpace is now positioned like no other company in the market,” said Glenn VandeGrift, President and Founder of CleanSpace. “We’re not just building cleanrooms. We’re delivering operationally ready GMP environments and providing our clients with a complete solution—through construction, CQV, and into long-term operation. That’s what true turnkey means, and that’s the new standard.”

Griffith’s proven ability to lead FDA-compliant initiatives, manage complex capital portfolios (including over $2B in sterile pharma expansion projects), and bridge technical operations with regulatory strategy will enable CleanSpace to provide a uniquely holistic offering for its clients.

“Robert’s background brings a rare depth to our executive team,” said Nicholas Vermont, Chief Operating Officer. “He’s been the client—he knows what success looks like on the other side of turnover. That insight is essential as we expand CleanShield and begin embedding ourselves deeper into our clients’ long-term success plans.”

“From technical documentation through CQV, Robert’s team will focus on getting our clients to GMP faster—with quality and reliability at the forefront,” said George Wiker, CEO and co-founder. “CleanSpace is now built to support our partners before, during, and well after construction. We’re raising the bar.”

As CleanSpace continues to build facilities for gene therapy, biologics, vaccine, and advanced therapeutics developers across the U.S., Griffith will help shape service delivery models that reduce time to GMP readiness and align technical execution with business-critical launch objectives.